Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753623 · ClinicalTrials.gov registry record · NA
Clinical Management of Neuropathic Pain With Ramelteon
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT00753623: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT00753623 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00753623, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This proposal is to conduct a double-blinded, randomized, placebo-controlled, crossover clinical study to examine the hypothesis that ramelteon would reduce pain score and improve functional status in subjects with neuropathic pain.
Interventions
- DRUG Placebo
- DRUG Ramelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00753623
The ClinicalTrials.gov registry entry for NCT00753623 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00753623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00753623 about?
NCT00753623 is a clinical study titled "Clinical Management of Neuropathic Pain With Ramelteon". This proposal is to conduct a double-blinded, randomized, placebo-controlled, crossover clinical study to examine the hypothesis that ramelteon would reduce pain score and improve functional status in subjects with neuropathic pain.
What is the current status of trial NCT00753623?
This trial is currently terminated. It is a NA study. The enrollment target is 23 participants. The study started on 2008-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00753623?
The interventions under investigation include: Placebo (DRUG), Ramelteon (DRUG).
Who is sponsoring clinical trial NCT00753623?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.